The Immuno Oncology Assays Market is expected to register a CAGR of 11% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The research report is segmented by Technology into Immunoassays, PCR, NGS, Flow Cytometry, and Others. Applications analyzed include Clinical Diagnostics, Research. Indication covered in the study are Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, Others. The global analysis is broken down by region and key countries, covering North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses.
Purpose of the ReportThe report Immuno Oncology Assays Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Immuno Oncology Assays Market Segmentation
Technology- Immunoassays
- PCR
- NGS
- Flow Cytometry
- Colorectal Cancer
- Lung Cancer
- Melanoma
- Bladder Cancer
- Clinical Diagnostics
- Research
Strategic Insights
Immuno Oncology Assays Market Growth Drivers- Increasing Incidence of Cancer: In 2024, an estimated 2,001,140 new cases of cancer will be diagnosed in the United States. Some of the key factors responsible for the growth of the immuno-oncology assays market include the increasing burden of cancer worldwide. The rising incidence and prevalence of several types of cancers add to the need for early diagnosis and treatment methods.
- Precision Medicine: Precision medicine offers healthcare providers the ability to present information that either validates or alters the trajectory of medical decisions. The Advancement of Precision Medicine has completely changed the nature of treating cancer by making treatments personalized for the individual profile of patients. Assays in immuno-oncology have grown into an indispensable component of this domain, given that they are highly required to give detailed insights into genetic and molecular tumor characteristics. The need for advanced diagnostic tools is further highlighted by the supportive role played by government and private healthcare organizations. These organizations are promoting cancer awareness through various programs. Immuno-oncology assays play an essential role in these cancer treatments because they help identify patients who are likely to benefit from immunotherapies, improve clinical outcomes, and help clinicians identify tumor-specific biomarkers that are necessary for customized treatment regimens. These assays are important in monitoring immune responses, selecting the most effective immunotherapy, and predicting treatment outcomes. Technology advancements, such as NGS and high-throughput screening, have considerably improved assay accuracy and efficiency. As precision medicine keeps evolving, these innovative immuno-oncology assays are further going to be demanded with growth drivers to expand the market.
- Increased Funding for Cancer Research: There is a rise in investment in cancer research from both government and private players. driven by increasing investment, immuno-oncology assays have remarkably grown. Various fundings focus on novel diagnostics and therapy to bring improved survival rates and quality of life in cancer patients. For instance, university partnerships have succeeded in speeding up assay development. Additionally, these partnerships succeeded in clinical validation procedures, in conjunction with biotech businesses. This flood of funds not only enhances R&D efforts but also allows the commercialization of sophisticated assays, thereby propelling the market share.
- Integration of AI in Oncology Assays: AI has a big impact on how we develop and use cancer tests and treatments. AI tools can handle and study huge amounts of data from genes, proteins, and immune systems. By spotting patterns humans can't see, AI helps predict how patients will react to certain immune treatments, pick the best markers to look for and speed up clinical trials. This cuts down the time it takes to create tests and makes them more accurate. AI systems also make tests better at predicting things by finding markers that show how cancer might avoid the immune system or resist treatment. Also, AI helps create better real-time tracking through wearable devices and quick, on-the-spot solutions letting doctors adjust treatment for each patient. As AI gets smarter, its use in cancer tests will make cancer care more precise and easy to access making it a must-have tool for doctors and researchers all over the world.
- Developments of Liquid Biopsy Assays: Liquid biopsy assays are revolutionizing cancer diagnostics by offering a non-invasive, efficient, and dynamic alternative to traditional tissue biopsies. Like traditional methods, in liquid biopsies, the following are tested from a simple blood sample: circulating tumor DNA (ctDNA), RNA, proteins, and exosomes. It decreases patient discomfort and risks associated with a procedure whereas repeated sampling can be done to track disease progression or response to treatment. Liquid biopsies are particularly useful in the detection of minimal residual disease and monitoring tumor heterogeneity, where traditional biopsies fail. Additionally, continuous improvements in NGS and ddPCR have increased the sensitivity and specificity of liquid biopsy assays.
- Toward Point-of-care testing solutions: These technologies are of special benefit in rural or resource-poor areas, where central laboratory access is not readily available. Furthermore, integration of smartphone-based platforms and cloud connectivity into POC devices enables convenient data sharing and remote monitoring. With the transformation of the healthcare environment worldwide to a patient-centered model, adoption of POC immuno-oncology assays is expected to rise, ensuring increased accessibility, decreased diagnostic delays, and eventually better patient outcomes.
- Rising Demand for Personalized Medicine in Immuno-Oncology: The growing focus on personalized medicine offers a tremendous opportunity for the immuno-oncology assays market. Immuno-oncology assays are critical in determining patient-specific biomarkers, such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI). These biomarkers guide specific treatment plans so that patients are given therapies that are most likely to be effective. Personalized medicine reduces trial-and-error approaches and minimizes adverse effects, which improve patient outcomes. The rapid development of next-generation sequencing (NGS) and multi-omics technologies is enabling assays to efficiently analyze complex biomarker networks. This, in turn, is increasing demand for innovative assay platforms that can deliver precise, patient-specific data. Additionally, with the trend of healthcare systems transitioning toward value-based care, personalized diagnostics will remain a priority area, thereby opening up a promising avenue for companies investing in advanced immuno-oncology assay solutions.
- Increasing Research and Development Spending on Immuno-Oncology: The increased R&D investments in immuno-oncology by pharmaceutical and biotechnology companies are associated with a large opportunity for the immuno-oncology assay market. These investments are boosting innovation in cancer diagnostics, therapy development, and discovery of biomarkers. The rising clinical trials targeting varied cancers are also increasing the demand for advanced assays for the assessment of immune responses and therapeutic efficacy. Government efforts and financial packages that promote accelerating research and innovation into cancer are added to market growth. In particular, it encourages strategic cooperation among academia, research institutes, and players in industry to develop novel technologies for next-generation assays. Some key companies that benefit from such growth by providing novel assay technologies, such as multiplex biomarker assays and immune-profiling tools, will be well-positioned to receive enough market share.
- Liquid Biopsy Technologies: Liquid biopsy technologies have the potential to revolutionize the immuno-oncology assays market as their adoption accelerates. The former, in contrast to traditional tissue biopsies, offers a minimally invasive approach for the monitoring of tumor dynamics and immune responses. Liquid biopsies enable the real-time tracking of circulating tumor DNA (ctDNA), exosomes, and immune cells and, therefore, can provide actionable insights into cancer progression and treatment response. Advances in digital PCR and NGS that are increasing the sensitivity and specificity of liquid biopsies mean this technology is becoming increasingly part of clinical practice. It will prove especially valuable in monitoring minimal residual disease and the mechanisms of resistance. As this demand for immuno-oncology application increases, those companies investing in the development of liquid biopsy assays are likely to see returns as healthcare providers search for innovative patient-friendly diagnostic solutions.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Immuno Oncology Assays Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Immuno Oncology Assays Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Immuno Oncology Assays Market is expected to register a CAGR of 11% from 2025-2031.
The major factors impacting the Immuno Oncology Assays Market are: Increased incidences of cancer and growth in precision medicine
Key future trends in Immuno oncology assays market are - Integration of AI in Oncology and development of liquid biopsy assays
Key companies of immuno oncology assays market are: Agilent Technologies, Inc,F. Hoffmann-La Roche Ltd,HTG Molecular Diagnostics, Inc., Illumina, Inc., Merck KGaA, PerkinElmer Inc., Thermo Fisher Scientific Inc., Qiagen, Sartorius AG, NanoString Technologies, Inc.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Immuno Oncology Assays Market - By Technology
1.3.2 Immuno Oncology Assays Market - By Indication
1.3.3 Immuno Oncology Assays Market - By Application
1.3.4 Immuno Oncology Assays Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. IMMUNO ONCOLOGY ASSAYS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. IMMUNO ONCOLOGY ASSAYS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. IMMUNO ONCOLOGY ASSAYS MARKET - GLOBAL MARKET ANALYSIS
6.1. IMMUNO ONCOLOGY ASSAYS - GLOBAL MARKET OVERVIEW
6.2. IMMUNO ONCOLOGY ASSAYS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. IMMUNO ONCOLOGY ASSAYS MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
7.1. OVERVIEW
7.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
7.3. IMMUNOASSAYS
7.3.1. Overview
7.3.2. Immunoassays Market Forecast and Analysis
7.4. PCR
7.4.1. Overview
7.4.2. PCR Market Forecast and Analysis
7.5. NGS
7.5.1. Overview
7.5.2. NGS Market Forecast and Analysis
7.6. FLOW CYTOMETRY
7.6.1. Overview
7.6.2. Flow Cytometry Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. IMMUNO ONCOLOGY ASSAYS MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. COLORECTAL CANCER
8.3.1. Overview
8.3.2. Colorectal Cancer Market Forecast and Analysis
8.4. LUNG CANCER
8.4.1. Overview
8.4.2. Lung Cancer Market Forecast and Analysis
8.5. MELANOMA
8.5.1. Overview
8.5.2. Melanoma Market Forecast and Analysis
8.6. BLADDER CANCER
8.6.1. Overview
8.6.2. Bladder Cancer Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. IMMUNO ONCOLOGY ASSAYS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. CLINICAL DIAGNOSTICS
9.3.1. Overview
9.3.2. Clinical Diagnostics Market Forecast and Analysis
9.4. RESEARCH
9.4.1. Overview
9.4.2. Research Market Forecast and Analysis
10. IMMUNO ONCOLOGY ASSAYS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Immuno Oncology Assays Market Overview
10.1.2 North America Immuno Oncology Assays Market Forecasts and Analysis
10.1.3 North America Immuno Oncology Assays Market Forecasts and Analysis - By Technology
10.1.4 North America Immuno Oncology Assays Market Forecasts and Analysis - By Indication
10.1.5 North America Immuno Oncology Assays Market Forecasts and Analysis - By Application
10.1.6 North America Immuno Oncology Assays Market Forecasts and Analysis - By Countries
10.1.6.1 United States Immuno Oncology Assays Market
10.1.6.1.1 United States Immuno Oncology Assays Market by Technology
10.1.6.1.2 United States Immuno Oncology Assays Market by Indication
10.1.6.1.3 United States Immuno Oncology Assays Market by Application
10.1.6.2 Canada Immuno Oncology Assays Market
10.1.6.2.1 Canada Immuno Oncology Assays Market by Technology
10.1.6.2.2 Canada Immuno Oncology Assays Market by Indication
10.1.6.2.3 Canada Immuno Oncology Assays Market by Application
10.1.6.3 Mexico Immuno Oncology Assays Market
10.1.6.3.1 Mexico Immuno Oncology Assays Market by Technology
10.1.6.3.2 Mexico Immuno Oncology Assays Market by Indication
10.1.6.3.3 Mexico Immuno Oncology Assays Market by Application
10.2. EUROPE
10.2.1 Europe Immuno Oncology Assays Market Overview
10.2.2 Europe Immuno Oncology Assays Market Forecasts and Analysis
10.2.3 Europe Immuno Oncology Assays Market Forecasts and Analysis - By Technology
10.2.4 Europe Immuno Oncology Assays Market Forecasts and Analysis - By Indication
10.2.5 Europe Immuno Oncology Assays Market Forecasts and Analysis - By Application
10.2.6 Europe Immuno Oncology Assays Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Immuno Oncology Assays Market
10.2.6.1.1 Germany Immuno Oncology Assays Market by Technology
10.2.6.1.2 Germany Immuno Oncology Assays Market by Indication
10.2.6.1.3 Germany Immuno Oncology Assays Market by Application
10.2.6.2 France Immuno Oncology Assays Market
10.2.6.2.1 France Immuno Oncology Assays Market by Technology
10.2.6.2.2 France Immuno Oncology Assays Market by Indication
10.2.6.2.3 France Immuno Oncology Assays Market by Application
10.2.6.3 Italy Immuno Oncology Assays Market
10.2.6.3.1 Italy Immuno Oncology Assays Market by Technology
10.2.6.3.2 Italy Immuno Oncology Assays Market by Indication
10.2.6.3.3 Italy Immuno Oncology Assays Market by Application
10.2.6.4 Spain Immuno Oncology Assays Market
10.2.6.4.1 Spain Immuno Oncology Assays Market by Technology
10.2.6.4.2 Spain Immuno Oncology Assays Market by Indication
10.2.6.4.3 Spain Immuno Oncology Assays Market by Application
10.2.6.5 United Kingdom Immuno Oncology Assays Market
10.2.6.5.1 United Kingdom Immuno Oncology Assays Market by Technology
10.2.6.5.2 United Kingdom Immuno Oncology Assays Market by Indication
10.2.6.5.3 United Kingdom Immuno Oncology Assays Market by Application
10.2.6.6 Rest of Europe Immuno Oncology Assays Market
10.2.6.6.1 Rest of Europe Immuno Oncology Assays Market by Technology
10.2.6.6.2 Rest of Europe Immuno Oncology Assays Market by Indication
10.2.6.6.3 Rest of Europe Immuno Oncology Assays Market by Application
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Immuno Oncology Assays Market Overview
10.3.2 Asia-Pacific Immuno Oncology Assays Market Forecasts and Analysis
10.3.3 Asia-Pacific Immuno Oncology Assays Market Forecasts and Analysis - By Technology
10.3.4 Asia-Pacific Immuno Oncology Assays Market Forecasts and Analysis - By Indication
10.3.5 Asia-Pacific Immuno Oncology Assays Market Forecasts and Analysis - By Application
10.3.6 Asia-Pacific Immuno Oncology Assays Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Immuno Oncology Assays Market
10.3.6.1.1 Australia Immuno Oncology Assays Market by Technology
10.3.6.1.2 Australia Immuno Oncology Assays Market by Indication
10.3.6.1.3 Australia Immuno Oncology Assays Market by Application
10.3.6.2 China Immuno Oncology Assays Market
10.3.6.2.1 China Immuno Oncology Assays Market by Technology
10.3.6.2.2 China Immuno Oncology Assays Market by Indication
10.3.6.2.3 China Immuno Oncology Assays Market by Application
10.3.6.3 India Immuno Oncology Assays Market
10.3.6.3.1 India Immuno Oncology Assays Market by Technology
10.3.6.3.2 India Immuno Oncology Assays Market by Indication
10.3.6.3.3 India Immuno Oncology Assays Market by Application
10.3.6.4 Japan Immuno Oncology Assays Market
10.3.6.4.1 Japan Immuno Oncology Assays Market by Technology
10.3.6.4.2 Japan Immuno Oncology Assays Market by Indication
10.3.6.4.3 Japan Immuno Oncology Assays Market by Application
10.3.6.5 South Korea Immuno Oncology Assays Market
10.3.6.5.1 South Korea Immuno Oncology Assays Market by Technology
10.3.6.5.2 South Korea Immuno Oncology Assays Market by Indication
10.3.6.5.3 South Korea Immuno Oncology Assays Market by Application
10.3.6.6 Rest of Asia-Pacific Immuno Oncology Assays Market
10.3.6.6.1 Rest of Asia-Pacific Immuno Oncology Assays Market by Technology
10.3.6.6.2 Rest of Asia-Pacific Immuno Oncology Assays Market by Indication
10.3.6.6.3 Rest of Asia-Pacific Immuno Oncology Assays Market by Application
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Immuno Oncology Assays Market Overview
10.4.2 Middle East and Africa Immuno Oncology Assays Market Forecasts and Analysis
10.4.3 Middle East and Africa Immuno Oncology Assays Market Forecasts and Analysis - By Technology
10.4.4 Middle East and Africa Immuno Oncology Assays Market Forecasts and Analysis - By Indication
10.4.5 Middle East and Africa Immuno Oncology Assays Market Forecasts and Analysis - By Application
10.4.6 Middle East and Africa Immuno Oncology Assays Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Immuno Oncology Assays Market
10.4.6.1.1 South Africa Immuno Oncology Assays Market by Technology
10.4.6.1.2 South Africa Immuno Oncology Assays Market by Indication
10.4.6.1.3 South Africa Immuno Oncology Assays Market by Application
10.4.6.2 Saudi Arabia Immuno Oncology Assays Market
10.4.6.2.1 Saudi Arabia Immuno Oncology Assays Market by Technology
10.4.6.2.2 Saudi Arabia Immuno Oncology Assays Market by Indication
10.4.6.2.3 Saudi Arabia Immuno Oncology Assays Market by Application
10.4.6.3 U.A.E Immuno Oncology Assays Market
10.4.6.3.1 U.A.E Immuno Oncology Assays Market by Technology
10.4.6.3.2 U.A.E Immuno Oncology Assays Market by Indication
10.4.6.3.3 U.A.E Immuno Oncology Assays Market by Application
10.4.6.4 Rest of Middle East and Africa Immuno Oncology Assays Market
10.4.6.4.1 Rest of Middle East and Africa Immuno Oncology Assays Market by Technology
10.4.6.4.2 Rest of Middle East and Africa Immuno Oncology Assays Market by Indication
10.4.6.4.3 Rest of Middle East and Africa Immuno Oncology Assays Market by Application
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Immuno Oncology Assays Market Overview
10.5.2 South and Central America Immuno Oncology Assays Market Forecasts and Analysis
10.5.3 South and Central America Immuno Oncology Assays Market Forecasts and Analysis - By Technology
10.5.4 South and Central America Immuno Oncology Assays Market Forecasts and Analysis - By Indication
10.5.5 South and Central America Immuno Oncology Assays Market Forecasts and Analysis - By Application
10.5.6 South and Central America Immuno Oncology Assays Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Immuno Oncology Assays Market
10.5.6.1.1 Brazil Immuno Oncology Assays Market by Technology
10.5.6.1.2 Brazil Immuno Oncology Assays Market by Indication
10.5.6.1.3 Brazil Immuno Oncology Assays Market by Application
10.5.6.2 Argentina Immuno Oncology Assays Market
10.5.6.2.1 Argentina Immuno Oncology Assays Market by Technology
10.5.6.2.2 Argentina Immuno Oncology Assays Market by Indication
10.5.6.2.3 Argentina Immuno Oncology Assays Market by Application
10.5.6.3 Rest of South and Central America Immuno Oncology Assays Market
10.5.6.3.1 Rest of South and Central America Immuno Oncology Assays Market by Technology
10.5.6.3.2 Rest of South and Central America Immuno Oncology Assays Market by Indication
10.5.6.3.3 Rest of South and Central America Immuno Oncology Assays Market by Application
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. IMMUNO ONCOLOGY ASSAYS MARKET, KEY COMPANY PROFILES
13.1. AGILENT TECHNOLOGIES, INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. F. HOFFMANN-LA ROCHE LTD
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. HTG MOLECULAR DIAGNOSTICS, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. ILLUMINA, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. MERCK KGAA
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. PERKINELMER INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. THERMO FISHER SCIENTIFIC INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. QIAGEN
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. SARTORIUS AG
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. NANOSTRING TECHNOLOGIES, INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Agilent Technologies, Inc.
2. F. Hoffmann-La Roche Ltd
3. HTG Molecular Diagnostics, Inc.
4. Illumina, Inc.
5. Merck KGaA
6. PerkinElmer Inc.
7. Thermo Fisher Scientific Inc.
8. Qiagen
9. Sartorius AG
10. NanoString Technologies, Inc.
11. Biomerieux SA
12. Myriad Genetics, Inc.
13. Guardant Health, Inc.
14. Bio-Rad Laboratories, Inc.
15. Seegene Inc.
16. Meso Scale Diagnostics, LLC
17. Olink
18. Asuragen, Inc.
19. Invivoscribe, Inc.
20. Creative Biolabs
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For